Stimulant Medication for Stimulant Use

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Stimulant Use+6 More
Adderall IR 10mg - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

Acute Effects of Stimulant Medication in College Students With ADHD

Eligible Conditions
  • Stimulant Use
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Mood
  • Working Memory
  • Change in Sustained Attention

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

7 Primary · 5 Secondary · Reporting Duration: Completed the day after each experimental appointment over a period of two weeks

Completed at baseline and each experimental appointment over a period of three weeks
Change in Continuous Performance Test - Identical Pairs (CPT-IP) for Adderall vs. Placebo
Change in Digit Span for Adderall vs. Placebo
Change in Letter-Number Sequencing for Adderall vs. Placebo
Change in Spatial Span (SS) for Adderall vs. Placebo
Completed the day after each experimental appointment over a period of two weeks
DSM-5 ADHD Symptoms Checklist - Modified (DSM 5-M)
Depression, Anxiety, and Stress Scale-Modified (DASS-M)
Pittsburgh Sleep Quality Index-Modified (PSQI-M)
Side Effects Rating Scale - Modified
Substance Use Day After Questionnaire
two weeks
Addiction Research Center Inventory (ARCI) for Adderall vs. Placebo
Intentions to Use Questionnaire (IUQ) for Adderall vs. Placebo
Visual Analogue Scales (VAS) for Adderall vs. Placebo

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Stimulant Medication
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: Stimulant Medication · Has Placebo Group · Phase 2

Stimulant MedicationExperimental Group · 2 Interventions: Adderall IR 10mg, Placebo · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: completed the day after each experimental appointment over a period of two weeks

Who is running the clinical trial?

University of WyomingLead Sponsor
15 Previous Clinical Trials
1,327 Total Patients Enrolled
Cynthia M Hartung, Ph.D.Principal Investigator - University of Wyoming
University of Wyoming
1 Previous Clinical Trials
48 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 12th, 2021

Last Reviewed: October 22nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
North Carolina50.0%
Tennessee50.0%
How old are they?
18 - 65100.0%
What site did they apply to?
University of Wyoming100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria50.0%
Met criteria50.0%

How responsive is this trial?

Average response time
  • < 1 Day
Most responsive sites:
  1. University of Wyoming: < 24 hours
Typically responds via
Phone Call100.0%